NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
| NRBODelisted Stock | USD 1.76 0.00 0.00% |
About 62% of Neurobo Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Neurobo Pharmaceuticals suggests that many traders are alarmed regarding Neurobo Pharmaceuticals' prospects. Neurobo Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Neurobo Pharmaceuticals. Many technical investors use Neurobo Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Neurobo |
NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of Part 1 of its two-part, Phase 2a clinical trial evaluating the efficacy and safety, of DA-1241, a novel G-Protein-Coupled Receptor 119 agonist for the treatment of metabolic dysfunction-associated steatohepatitis . Approximately 49 patients with presumed MASH have been randomized into Part 1 with a 1
Read at finance.yahoo.com
 |
Neurobo Pharmaceuticals Fundamental Analysis
We analyze Neurobo Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Cash Per Share
Cash Per Share Comparative Analysis
Neurobo Pharmaceuticals is currently under evaluation in cash per share category among its peers. Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Neurobo Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurobo Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Neurobo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neurobo Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Neurobo Pharmaceuticals Related Equities
| REVB | Revelation Biosciences | 43.48 | ||||
| CDIO | Cardio Diagnostics | 12.20 | ||||
| VRAX | Virax Biolabs | 9.22 | ||||
| KPRX | Kiora Pharmaceuticals | 8.48 | ||||
| QNRX | Quoin Pharmaceuticals | 3.08 | ||||
| BDRX | Biodexa Pharmaceticals | 0.99 | ||||
| SONN | Sonnet Biotherapeutics | 1.35 | ||||
| ALLR | Allarity Therapeutics | 5.13 | ||||
| PHIO | Phio Pharmaceuticals | 5.26 | ||||
| ZURA | Zura Bio | 6.00 | ||||
| ATNF | 180 Life | 6.19 |
Check out Neurobo Pharmaceuticals Hype Analysis, Neurobo Pharmaceuticals Correlation and Neurobo Pharmaceuticals Performance. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Stocks Directory Find actively traded stocks across global markets | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device |